1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related
  4. Interleukin Related Ligand

Interleukin Related Ligand

Interleukin Related Ligands (6):

Cat. No. Product Name Effect Purity
  • HY-P991144
    Lasrekibart
    Ligand
    Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma.
  • HY-P990708
    Bizaxofusp
    Ligand
    Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer.
  • HY-P991129
    Crusekitug
    Ligand
    Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis.
  • HY-P991162
    Tilrekimig
    Ligand
    Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis.
  • HY-P991146
    Lecankitug
    Ligand
    Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis.
  • HY-N9086A
    (rac)-Poriol
    Ligand
    (rac)-Poriol (5,7,4'-Trihydroxy-6-methylflavanone) exhibits antioxidant activity, and scavenges free radical DPPH with an IC50 of 0.18 µg/mL. (rac)-Poriol inhibits the LPS (HY-D1056)-induced NO generation in RAW264.7 (98.35% inhibition rate at 10 μM), and exhibits anti-inflammatory activity. (rac)-Poriol exhibits good binding affinity with iNOS, COX-1, COX-2, TNF-α, and IL-1β.